Logo

American Heart Association

  30
  0


Final ID:

The synergistic impact of Diabetes and CKD on Cardiovascular Risk and Mortality

  • Pandey, Ambarish  ( UTSW , Dallas , Texas , United States )
  • Deboer, Ian  ( University of Washington , Seattle , Washington , United States )
  • Author Disclosures:
    Ambarish Pandey: DO have relevant financial relationships ; Consultant:Tricog:Active (exists now) ; Consultant:Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Anumana, Alleviant, Pfizer, Abbott, Axon Therapies, Kilele Health, Acorai, Kardigan, Novartis, Idorsia Pharma, and Science37:Active (exists now) ; Consultant:Rivus:Active (exists now) ; Consultant:iRhythm:Active (exists now) ; Researcher:SQ innovations:Active (exists now) ; Research Funding (PI or named investigator):SC Pharma:Active (exists now) ; Consultant:Astra Zeneca:Active (exists now) ; Research Funding (PI or named investigator):Ultromics:Active (exists now) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Consultant:Ultromics:Active (exists now) ; Consultant:Roche:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) | IAN DEBOER: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Diabetes, CKD and CVD Risk: From Mechanisms to Management

Saturday, 11/08/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available